Inactive Instrument

Analyst Reco. Afya Limited Nasdaq

Equities

JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22	11-27	MT
Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating	22/11/22	MT
UBS Adjusts Afya Price Target to $18 From $21, Maintains Buy Rating	13/10/22	MT
Credit Suisse Upgrades Afya to Outperform from Neutral, Adjusts Price Target to $19 from $18	08/04/22	MT
UBS Adjusts Afya Price Target to $21 From $27, Maintains Buy Rating	07/03/22	MT
Goldman Sachs Adjusts Afya's Price Target to $19 From $29, Reiterates Buy Rating	15/02/22	MT
Afya : Sustainalytics ESG Risk Rating Is Publicly Available	28/09/21	BU
Afya : Sustainalytics ESG Risk Rating is Publicly Available	28/09/21	PU
AFYA : Morgan Stanley Downgrades Afya to Equalweight from Overweight, Adjusts Price Target to $28.50 from $32	21/07/21	MT
AFYA : UBS Upgrades Afya to Buy From Neutral, Citing Recent Sell-Off, Resiliency, Cash Generation; Price Target to $27 From $29.50	15/04/21	MT
AFYA : JPMorgan Upgrades Afya to Overweight From Neutral; Price Target is $34	04/02/21	MT

No results for this search